FindTrial
Sign In

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Disseminated Mycobacterium Avium Complex Disease (MAC) in AIDS Patients Who Are Receiving Standard Acute Treatment for This Opportunistic Infection

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002170
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Mycobacterium Avium-Intracellulare Infection

Keywords

AIDS-Related Opportunistic Infections, Placebos, Mycobacterium avium-intracellulare Infection, Acquired Immunodeficiency Syndrome, HIV Protease Inhibitors, Nelfinavir, Anti-Infective Agents, Anti-HIV Agents

Brief summary

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.

Interventions

DRUGNelfinavir mesylate

Sponsors

Agouron Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must have: * HIV infection * New diagnosis of MAC bacteremia and \< 7 days of therapy. Prior Medication: Allowed: Patients no more than 7 days of therapy for MAC disease.

Exclusion criteria

Prior Medication: Excluded: Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026